These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33731990)

  • 1. Economic Burden of COPD by Disease Severity - A Nationwide Cohort Study in Denmark.
    Løkke A; Lange P; Lykkegaard J; Ibsen R; Andersson M; de Fine Licht S; Hilberg O
    Int J Chron Obstruct Pulmon Dis; 2021; 16():603-613. PubMed ID: 33731990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
    Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
    J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population.
    Pasquale MK; Sun SX; Song F; Hartnett HJ; Stemkowski SA
    Int J Chron Obstruct Pulmon Dis; 2012; 7():757-64. PubMed ID: 23152680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease Trajectories and Impact of One Moderate Exacerbation in Gold B COPD Patients.
    Løkke A; Hilberg O; Lange P; Ibsen R; Stratelis G; de Fine Licht S; Lykkegaard J
    Int J Chron Obstruct Pulmon Dis; 2022; 17():569-578. PubMed ID: 35321533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
    Palli SR; Zhou S; Shaikh A; Willey VJ
    J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review.
    Iheanacho I; Zhang S; King D; Rizzo M; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2020; 15():439-460. PubMed ID: 32161455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET.
    Byng D; Lutter JI; Wacker ME; Jörres RA; Liu X; Karrasch S; Schulz H; Vogelmeier C; Holle R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1423-1439. PubMed ID: 31308648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic burden of COPD in a Swedish cohort: the ARCTIC study.
    Lisspers K; Larsson K; Johansson G; Janson C; Costa-Scharplatz M; Gruenberger JB; Uhde M; Jorgensen L; Gutzwiller FS; Ställberg B
    Int J Chron Obstruct Pulmon Dis; 2018; 13():275-285. PubMed ID: 29391785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population.
    Sethi S; Make BJ; Robinson SB; Kumar S; Pollack M; Moretz C; Dreyfus J; Xi A; Powell D; Feigler N
    Int J Chron Obstruct Pulmon Dis; 2022; 17():593-608. PubMed ID: 35342290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct and indirect costs of COPD progression and its comorbidities in a structured disease management program: results from the LQ-DMP study.
    Kirsch F; Schramm A; Schwarzkopf L; Lutter JI; Szentes B; Huber M; Leidl R
    Respir Res; 2019 Oct; 20(1):215. PubMed ID: 31601216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COPD management costs according to the frequency of COPD exacerbations in UK primary care.
    Punekar YS; Shukla A; Müllerova H
    Int J Chron Obstruct Pulmon Dis; 2014; 9():65-73. PubMed ID: 24426781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study.
    Gedebjerg A; Szépligeti SK; Wackerhausen LH; Horváth-Puhó E; Dahl R; Hansen JG; Sørensen HT; Nørgaard M; Lange P; Thomsen RW
    Lancet Respir Med; 2018 Mar; 6(3):204-212. PubMed ID: 29331311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COPD exacerbations by disease severity in England.
    Merinopoulou E; Raluy-Callado M; Ramagopalan S; MacLachlan S; Khalid JM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():697-709. PubMed ID: 27099486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].
    Jahnz-Rózyk K; Targowski T; From S
    Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Burden Of Chronic Obstructive Pulmonary Disease (COPD) In Finland: Impact Of Disease Severity And Eosinophil Count On Healthcare Resource Utilization.
    Viinanen A; Lassenius MI; Toppila I; Karlsson A; Veijalainen L; Idänpään-Heikkilä JJ; Laitinen T
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2409-2421. PubMed ID: 31749614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The annual direct costs of stable COPD in Greece.
    Stafyla E; Geitona M; Kerenidi T; Economou A; Daniil Z; Gourgoulianis KI
    Int J Chron Obstruct Pulmon Dis; 2018; 13():309-315. PubMed ID: 29398912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
    Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
    Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.
    Wan Y; Sun SX; Corman S; Huang X; Gao X; Shorr AF
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2127-36. PubMed ID: 26504378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical And Economic Burden Of Eosinophilic COPD In A Large Retrospective US Cohort.
    Trudo F; Kallenbach L; Vasey J; Chung Y; Wilk A; Slipski L; O'Brien D; Strange C
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2625-2637. PubMed ID: 32063703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eosinophil counts in first COPD hospitalizations: a 1-year cost analysis in Quebec, Canada.
    Poder TG; Carrier N; Bélanger M; Couillard S; Courteau J; Larivée P; Vanasse A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3065-3076. PubMed ID: 30349220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.